[{"address1": "No. 6, Shennong Road", "address2": "Torch Development Zone", "city": "Zhongshan", "zip": "528437", "country": "China", "phone": "86 76 0898 73998", "fax": "86 76 0898 73900", "website": "https://www.akesobio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Akeso, Inc., a biopharmaceutical company, researches, develops, manufactures, and commercializes antibody drugs. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer (GC), gastroesophageal junction (GEJ) cancer, ESCC, hepatocellular carcinoma (HCC), small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), pancreatic cancer, and solid tumors; and AK112, a PD-1/VEGF bi-specific antibody to treat NSCLC, triple-negative breast cancer (TNBC), head and neck cancer, HCC, colorectal and ovarian cancer, and solid tumors. It is also developing AK117, a CD47 monoclonal antibody to treat myelodysplastic syndrome, acute myeloid leukemia, GC, GEJ, ESCC, HNSCC, CRC, TNBC, and solid tumors/lymphoma; AK105, a PD-1 monoclonal antibody to treat classic Hodgkin's lymphoma (R/R cHL), NSCLC, NPC, HCC, SCLC, thyroid cancer, mesothelioma and thymic cancer, ESCC, UC, GC, GEJ, cholangiocarcinoma, neuroendocrine tumor, and mismatch repair deficient solid tumor; AK119, a CD73 monoclonal antibody for treating solid tumors and NSCLC; and AK109, a VEGFR-2 monoclonal antibody to treat GC, GEJ, NSCLC, HCC, and solid tumors. In addition, the company develops AK102, a PCSK9 monoclonal antibody to treat hypercholesterolemia and mixed hyperlipidemia; AK101, an IL-12/IL-23 monoclonal antibody to treat moderate-to-severe psoriasis and ulcerative colitis; AK111, an IL-17 monoclonal antibody to treat moderate-to-severe psoriasis and ankylosing spondylitis; and AK120, an IL-4R monoclonal antibody to treat moderate-to-severe atopic dermatitis. Further, its preclinical product includes AK127, a TIGIT monoclonal antibody to treat solid tumors; and AK115, a NGF monoclonal antibody. The company has collaboration agreements with Pfizer Pharmaceuticals; AstraZeneca Pharmaceuticals; Summit Therapeutics Inc.; and Shenzhen Chipscreen Biosciences Co., Ltd. Akeso, Inc. was founded in 2012 and is headquartered in Zhongshan, the People's Republic of China.", "fullTimeEmployees": 2815, "companyOfficers": [{"maxAge": 1, "name": "Dr. Yu  Xia Ph.D.", "age": 56, "title": "Founder, CEO, President & Chairwoman", "yearBorn": 1967, "fiscalYear": 2023, "totalPay": 915637, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Baiyong  Li Ph.D.", "age": 54, "title": "Co-Founder, Executive VP, CSO & Executive Director", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 703991, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Zhongmin  Wang Ph.D.", "age": 54, "title": "Co-Founder, Senior VP & Executive Director", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 504695, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Peng  Zhang Ph.D.", "age": 47, "title": "Co-Founder, Senior VP & Executive Director", "yearBorn": 1976, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Bing C. Wang M.B.A., Ph.D.", "age": 46, "title": "Chief Financial Officer", "yearBorn": 1977, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Xinfeng  Zhang", "title": "Senior Vice President", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Wenjun  Shi", "title": "Senior Vice President", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Mingxiu  Hu Ph.D.", "title": "Senior Vice President", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Charlie  Zhang Ph.D.", "title": "Senior Vice President", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jing  Min Ph.D.", "title": "Senior Vice President", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 4.62, "open": 4.62, "dayLow": 4.62, "dayHigh": 4.62, "regularMarketPreviousClose": 4.62, "regularMarketOpen": 4.62, "regularMarketDayLow": 4.62, "regularMarketDayHigh": 4.62, "beta": 0.522, "trailingPE": 16.705881, "volume": 177, "regularMarketVolume": 177, "averageVolume": 169, "averageVolume10days": 67, "averageDailyVolume10Day": 67, "bid": 4.05, "ask": 6.53, "marketCap": 5423820288, "fiftyTwoWeekLow": 4.3, "fiftyTwoWeekHigh": 6.45, "priceToSalesTrailing12Months": 2.8940346, "fiftyDayAverage": 5.22406, "twoHundredDayAverage": 5.7220325, "currency": "USD", "enterpriseValue": 5057474560, "profitMargins": -0.39236, "floatShares": 550242642, "sharesOutstanding": 865857024, "heldPercentInsiders": 0.26473, "heldPercentInstitutions": 0.33315, "impliedSharesOutstanding": 954897984, "bookValue": 6.186, "priceToBook": 0.9182024, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -735334976, "trailingEps": 0.34, "enterpriseToRevenue": 2.699, "enterpriseToEbitda": -6.261, "52WeekChange": 0.13600004, "SandP52WeekChange": 0.24014747, "exchange": "PNK", "quoteType": "EQUITY", "symbol": "AKESF", "underlyingSymbol": "AKESF", "shortName": "AKESO INC.", "longName": "Akeso, Inc.", "firstTradeDateEpochUtc": 1684330200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "345333bf-d483-3754-bfdc-082241fc85f3", "messageBoardId": "finmb_660797233", "gmtOffSetMilliseconds": -14400000, "currentPrice": 5.68, "recommendationKey": "none", "totalCash": 2974273024, "totalCashPerShare": 3.521, "ebitda": -807769472, "totalDebt": 3318097920, "quickRatio": 2.439, "currentRatio": 4.786, "totalRevenue": 1874137984, "debtToEquity": 64.536, "revenuePerShare": 2.228, "returnOnAssets": -0.060110003, "returnOnEquity": -0.15630999, "freeCashflow": -3421471744, "operatingCashflow": -749971008, "revenueGrowth": -0.721, "grossMargins": 0.92428, "ebitdaMargins": -0.43101, "operatingMargins": -0.37313998, "financialCurrency": "CNY", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]